EDIT
Price
$2.83
Change
+$0.02 (+0.71%)
Updated
Jun 3, 01:08 PM (EDT)
Capitalization
512.56M
63 days until earnings call
Intraday BUY SELL Signals
STOK
Price
$28.89
Change
+$0.21 (+0.73%)
Updated
Jun 3, 01:21 PM (EDT)
Capitalization
1.79B
68 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

EDIT vs STOK

Header iconEDIT vs STOK Comparison
Open Charts EDIT vs STOKBanner chart's image
EDIT vs STOK Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
EDIT vs. STOK commentary
Jun 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and STOK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 03, 2026
Stock price -- (EDIT: $2.82 vs. STOK: $28.68)
Brand notoriety: EDIT and STOK are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EDIT: 182% vs. STOK: 107%
Market capitalization -- EDIT: $512.56M vs. STOK: $1.79B
EDIT [@Biotechnology] is valued at $512.56M. STOK’s [@Biotechnology] market capitalization is $1.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.89B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EDIT’s FA Score shows that 0 FA rating(s) are green whileSTOK’s FA Score has 1 green FA rating(s).

  • EDIT’s FA Score: 0 green, 5 red.
  • STOK’s FA Score: 1 green, 4 red.
According to our system of comparison, STOK is a better buy in the long-term than EDIT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EDIT’s TA Score shows that 5 TA indicator(s) are bullish while STOK’s TA Score has 3 bullish TA indicator(s).

  • EDIT’s TA Score: 5 bullish, 6 bearish.
  • STOK’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than STOK.

Price Growth

EDIT (@Biotechnology) experienced а -8.60% price change this week, while STOK (@Biotechnology) price change was -7.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.00%. For the same industry, the average monthly price growth was -2.47%, and the average quarterly price growth was +2.80%.

Reported Earning Dates

EDIT is expected to report earnings on Aug 05, 2026.

STOK is expected to report earnings on Aug 10, 2026.

Industries' Descriptions

@Biotechnology (-2.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
STOK($1.79B) has a higher market cap than EDIT($513M). EDIT YTD gains are higher at: 37.317 vs. STOK (-9.641). EDIT has higher annual earnings (EBITDA): -100.08M vs. STOK (-183.52M). STOK has more cash in the bank: 344M vs. EDIT (124M). STOK has less debt than EDIT: STOK (2.43M) vs EDIT (17.3M). EDIT has higher revenues than STOK: EDIT (38.7M) vs STOK (32.1M).
EDITSTOKEDIT / STOK
Capitalization513M1.79B29%
EBITDA-100.08M-183.52M55%
Gain YTD37.317-9.641-387%
P/E RatioN/A48.34-
Revenue38.7M32.1M121%
Total Cash124M344M36%
Total Debt17.3M2.43M711%
FUNDAMENTALS RATINGS
EDIT vs STOK: Fundamental Ratings
EDIT
STOK
OUTLOOK RATING
1..100
8962
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
85
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
3741
P/E GROWTH RATING
1..100
1004
SEASONALITY SCORE
1..100
9026

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

STOK's Valuation (85) in the null industry is in the same range as EDIT (86) in the Biotechnology industry. This means that STOK’s stock grew similarly to EDIT’s over the last 12 months.

STOK's Profit vs Risk Rating (100) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that STOK’s stock grew similarly to EDIT’s over the last 12 months.

STOK's SMR Rating (99) in the null industry is in the same range as EDIT (100) in the Biotechnology industry. This means that STOK’s stock grew similarly to EDIT’s over the last 12 months.

EDIT's Price Growth Rating (37) in the Biotechnology industry is in the same range as STOK (41) in the null industry. This means that EDIT’s stock grew similarly to STOK’s over the last 12 months.

STOK's P/E Growth Rating (4) in the null industry is significantly better than the same rating for EDIT (100) in the Biotechnology industry. This means that STOK’s stock grew significantly faster than EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EDITSTOK
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 7 days ago
86%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
EDIT
Daily Signal:
Gain/Loss:
STOK
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
USML43.720.90
+2.09%
ETRACS 2x Lvrgd MSCI US Mn Vl Fct TR ETN
DRNZ29.150.37
+1.29%
REX Drone ETF
RSSE22.840.04
+0.18%
FT Vest U.S. Eq Eql Wght Buffr ETF - Sep
FUMB20.05N/A
N/A
First Trust Ultra Short Dur Muncpl ETF
GGLL119.31-10.04
-7.76%
Direxion Daily GOOGL Bull 2X Shares

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with CRBU. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then CRBU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
-15.72%
CRBU - EDIT
64%
Loosely correlated
-4.32%
BEAM - EDIT
60%
Loosely correlated
-7.00%
NTLA - EDIT
57%
Loosely correlated
-4.37%
CRSP - EDIT
56%
Loosely correlated
-4.00%
PRME - EDIT
54%
Loosely correlated
-5.59%
More

STOK and

Correlation & Price change

A.I.dvisor indicates that over the last year, STOK has been loosely correlated with QTTB. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then QTTB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STOK
1D Price
Change %
STOK100%
-5.87%
QTTB - STOK
49%
Loosely correlated
+8.83%
RCKT - STOK
48%
Loosely correlated
-4.30%
EDIT - STOK
44%
Loosely correlated
-15.72%
BCYC - STOK
39%
Loosely correlated
-5.08%
CRBU - STOK
39%
Loosely correlated
-4.32%
More